LONG-TERM BENEFIT OF COSENTYX IN ANKYLOSING SPONDYLITIS NEWS TIPS & FEATURES

Long-term Benefit of Cosentyx in Ankylosing Spondylitis

January 22, 2018

Long-term Benefit of Cosentyx in Ankylosing Spondylitis

By cancerconnect cancerconnect

Spine Community News: Cosentyx (secukinumab) is an anti-interleukin-17A monoclonal antibody that is approved for the treatment of ankylosing spondylitis (AS).  […]

View full entry

Tags: Ankylosing Spondylitis, anti-interleukin-17A, Cosentyx, Dr Borenstein, News Tips and Features, secukinumab, Spine Community News


Cosentyx: Good News For Ankylosing Spondylitis Patients

December 14, 2017

Cosentyx: Good News For Ankylosing Spondylitis Patients

By cancerconnect cancerconnect

Spine Community News: Doctors recently updated the results of the MEASURE 1 extension clinical trial designed to evaluate Cosentyx (secukinumab) […]

View full entry

Tags: Ankylosing Spondylitis, AS, clinical trial, Cosentyx, extension, interleukin 17, MEASURE 1, News Tips and Features, secukinumab


Cosentyx Highly Effective for Treatment of Scalp Psoriasis

September 25, 2017

Cosentyx Highly Effective for Treatment of Scalp Psoriasis

By cancerconnect cancerconnect

Psoriasis is a chronic skin condition caused by an overactive immune system affecting 1-3% of people in the United States. […]

View full entry

Tags: Cosentyx, interleukin 17A, News Tips and Features, plaque psoriasis, Psoriatic Arthritis, secukinumab


CONDITIONS OF THE GI TRACT